hotspot -WSS

hotspot

author：comprehensive 2025-10-01 00:52:58 - browse：658

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Petition to FDA: Get the lead out of consumer hair dyes

WSS

Palantir health business leans on meeting customers’ needs

N.Y. state detects polio case, first in the U.S. since 2013

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

Adele warns fans about throwing things at performers onstage

Why 40% Americans with Parkinson’s don’t see a neurologist

Israel withdraws forces after 2

leisure time

hotspot

entertainment

Medicare details structure of new drug price negotiation program

How the political right came to back psychedelics to treat trauma

United colonoscopy coverage change 'may cost lives,' doctors say

Leqembi, other new Alzheimer’s drugs require better biomarkers

Medicare details structure of new drug price negotiation program

Pope Francis asks Church to identify 21st

Duchenne breakthrough therapy leaves behind pioneering families

Oak trusses raised to roof of fire

Alkermes shareholders re

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

Wikipedia

Living with Fabry disease, a condition that causes chronic pain

Pope Francis asks Church to identify 21st

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

Beach reads and more: STAT's 2023 summer book list

Pentagon will tighten controls on classified information after Discord leak

Adele warns fans about throwing things at performers onstage

hotspot

leisure time

hotspot

leisure time